BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(45): 16841-16857 [PMID: 25492998 DOI: 10.3748/wjg.v20.i45.16841] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Velázquez KT, Enos RT, Bader JE, Sougiannis AT, Carson MS, Chatzistamou I, Carson JA, Nagarkatti PS, Nagarkatti M, Murphy EA. Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice. World J Hepatol 2019; 11(8): 619-637 [PMID: 31528245 DOI: 10.4254/wjh.v11.i8.619] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 24.0] [Reference Citation Analysis]
2 Park H, Liu Y, Kim HS, Shin JH. Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease. Nutr Res 2016;36:57-64. [PMID: 26773781 DOI: 10.1016/j.nutres.2015.10.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
3 You MM, Liu YC, Chen YF, Pan YM, Miao ZN, Shi YZ, Si JJ, Chen ML, Hu FL. Royal jelly attenuates nonalcoholic fatty liver disease by inhibiting oxidative stress and regulating the expression of circadian genes in ovariectomized rats. J Food Biochem 2020;44:e13138. [PMID: 31894585 DOI: 10.1111/jfbc.13138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lee HJ, Cui R, Choi SE, Jeon JY, Kim HJ, Kim TH, Kang Y, Lee KW. Bitter melon extract ameliorates palmitate-induced apoptosis via inhibition of endoplasmic reticulum stress in HepG2 cells and high-fat/high-fructose-diet-induced fatty liver. Food Nutr Res 2018;62. [PMID: 30026676 DOI: 10.29219/fnr.v62.1319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wen B, Zhang C, Zhou J, Zhang Z, Che Q, Cao H, Bai Y, Guo J, Su Z. Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways. Pharmacol Ther 2021;222:107752. [PMID: 33253739 DOI: 10.1016/j.pharmthera.2020.107752] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Khoo WY, Chrisfield BJ, Sae-Tan S, Lambert JD. Mitigation of nonalcoholic fatty liver disease in high-fat-fed mice by the combination of decaffeinated green tea extract and voluntary exercise. J Nutr Biochem 2020;76:108262. [PMID: 31759197 DOI: 10.1016/j.jnutbio.2019.108262] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Al Sharif M, Alov P, Vitcheva V, Diukendjieva A, Mori M, Botta B, Tsakovska I, Pajeva I. Natural modulators of nonalcoholic fatty liver disease: Mode of action analysis and in silico ADME-Tox prediction. Toxicology and Applied Pharmacology 2017;337:45-66. [DOI: 10.1016/j.taap.2017.10.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
8 Gonzalez Rozas M, Hernanz Roman L, Gonzalez DG, Pérez-Castrillón JL. Panhypopituitarism due to Absence of the Pituitary Stalk: A Rare Aetiology of Liver Cirrhosis. Case Rep Endocrinol 2016;2016:9071097. [PMID: 27213061 DOI: 10.1155/2016/9071097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Duarte SMB, Stefano JT, Vanni DS, Carrilho FJ, Oliveira CPMS. IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Arq Gastroenterol 2019;56:431-9. [PMID: 31721969 DOI: 10.1590/S0004-2803.201900000-67] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
10 Federico A, Dallio M, Gravina AG, Diano N, Errico S, Masarone M, Romeo M, Tuccillo C, Stiuso P, Morisco F, Persico M, Loguercio C. The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. Int J Environ Res Public Health 2020;17:E3369. [PMID: 32408667 DOI: 10.3390/ijerph17103369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
11 Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Malhotra N, Beaton MD. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol 2017; 23(1): 141-150 [PMID: 28104990 DOI: 10.3748/wjg.v23.i1.141] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 69] [Article Influence: 20.0] [Reference Citation Analysis]
12 Roeb E, Canbay A. Nichtalkoholische Fettlebererkrankungen. Gastroenterologe 2016;11:205-15. [DOI: 10.1007/s11377-016-0063-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Siddiqui MT, Amin H, Garg R, Chadalavada P, Al-Yaman W, Lopez R, Singh A. Medications in type-2 diabetics and their association with liver fibrosis. World J Gastroenterol 2020; 26(23): 3249-3259 [PMID: 32684739 DOI: 10.3748/wjg.v26.i23.3249] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol 2017;2:211-23. [PMID: 28404136 DOI: 10.1016/S2468-1253(16)30120-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
15 Malhotra N, Beaton MD. Management of non-alcoholic fatty liver disease in 2015. World J Hepatol 2015; 7(30): 2962-2967 [PMID: 26730275 DOI: 10.4254/wjh.v7.i30.2962] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
16 Dibba P, Li AA, Perumpail BJ, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. Diseases 2018;6:E83. [PMID: 30235807 DOI: 10.3390/diseases6030083] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
17 Kostrzewski T, Cornforth T, Snow SA, Ouro-Gnao L, Rowe C, Large EM, Hughes DJ. Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(2): 204-215 [PMID: 28127194 DOI: 10.3748/wjg.v23.i2.204] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 17.3] [Reference Citation Analysis]
18 Lama A, Pirozzi C, Mollica MP, Trinchese G, Di Guida F, Cavaliere G, Calignano A, Mattace Raso G, Berni Canani R, Meli R. Polyphenol-rich virgin olive oil reduces insulin resistance and liver inflammation and improves mitochondrial dysfunction in high-fat diet fed rats. Mol Nutr Food Res 2017;61. [PMID: 27794174 DOI: 10.1002/mnfr.201600418] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
19 Song L, Zhao XG, Ouyang PL, Guan Q, Yang L, Peng F, Du H, Yin F, Yan W, Yu WJ, Yan H. Combined effect of n -3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial. Br J Nutr 2020;123:1148-58. [DOI: 10.1017/s0007114520000495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
20 Zhang JM, Wang XH, Hao LH, Wang H, Zhang XY, Muhammad I, Qi Y, Li GL, Sun XQ. Nrf2 is crucial for the down-regulation of Cyp7a1 induced by arachidonic acid in Hepg2 cells. Environ Toxicol Pharmacol 2017;52:21-6. [PMID: 28364638 DOI: 10.1016/j.etap.2017.03.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
21 Jin ES, Sherry AD, Malloy CR. An Oral Load of [13C3]Glycerol and Blood NMR Analysis Detect Fatty Acid Esterification, Pentose Phosphate Pathway, and Glycerol Metabolism through the Tricarboxylic Acid Cycle in Human Liver. J Biol Chem 2016;291:19031-41. [PMID: 27432878 DOI: 10.1074/jbc.M116.742262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
22 Swallah MS, Fan H, Wang S, Yu H, Piao C. Prebiotic Impacts of Soybean Residue (Okara) on Eubiosis/Dysbiosis Condition of the Gut and the Possible Effects on Liver and Kidney Functions. Molecules 2021;26:E326. [PMID: 33440603 DOI: 10.3390/molecules26020326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Sinha RA, Yen PM. Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD. Cell Biosci 2016;6:46. [PMID: 27437098 DOI: 10.1186/s13578-016-0113-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
24 Sokolovska J, Isajevs S, Rostoka E, Sjakste T, Trapiņa I, Ošiņa K, Paramonova N, Sjakste N. Changes in glucose transporter expression and nitric oxide production are associated with liver injury in diabetes. Cell Biochem Funct 2015;33:367-74. [PMID: 26347179 DOI: 10.1002/cbf.3123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
25 Zhou Y, Li P, Wang X, Wu C, Fan N, Liu X, Wu L, Zhang W, Zhang W, Liu Z, Tang B. In situ visualization of peroxisomal viscosity in the liver of mice with non-alcoholic fatty liver disease by near-infrared fluorescence and photoacoustic imaging. Chem Sci 2020;11:12149-56. [PMID: 34094429 DOI: 10.1039/d0sc02922j] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 15.0] [Reference Citation Analysis]
26 Pohl R, Rein-fischboeck L, Meier EM, Eisinger K, Krautbauer S, Buechler C. Resolvin E1 and chemerin C15 peptide do not improve rodent non-alcoholic steatohepatitis. Experimental and Molecular Pathology 2015;98:295-9. [DOI: 10.1016/j.yexmp.2015.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
27 Jin H, Xu X, Pang B, Yang R, Sun H, Jiang C, Shao D, Shi J. Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Benef Microbes 2021;:1-14. [PMID: 34511051 DOI: 10.3920/BM2020.0183] [Reference Citation Analysis]
28 Golabi P, Locklear CT, Austin P, Afdhal S, Byrns M, Gerber L, Younossi ZM. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World J Gastroenterol 2016; 22(27): 6318-6327 [PMID: 27468220 DOI: 10.3748/wjg.v22.i27.6318] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 60] [Article Influence: 14.4] [Reference Citation Analysis]
29 Jiang W, Guo MH, Hai X. Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat. World J Gastroenterol 2016; 22(46): 10180-10188 [PMID: 28028366 DOI: 10.3748/wjg.v22.i46.10180] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 47] [Article Influence: 11.8] [Reference Citation Analysis]